You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is the structure of Rezvoglar™ (insulin glargine‑aglr) and Basaglar® (insulin glargine) the same?
Rezvoglar has an identical amino acid sequence to that of Basaglar.
Structure of Rezvoglar
Rezvoglar™ (insulin glargine-aglr) 100 units/mL and Basaglar® (insulin glargine) 100 units/mL have an identical amino acid sequence.1,2
Rezvoglar has a different amino acid sequence to that of human insulin (Structure of Rezvoglar Compared With Human Insulin).1
Position |
Rezvoglar |
Human Insulin |
A21 |
Glycine |
Asparagine |
C-terminus of the beta chain |
Addition of 2 arginines |
NA |
Abbreviations: NA = not applicable; Rezvoglar = Rezvoglar™ (insulin glargine-aglr) 100 units/mL.
Enclosed Prescribing Information
References
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: February 21, 2025